Therapy Areas: Respiratory
ZandCell unveils world's first saliva based antigen Coronavirus test
16 September 2020 -

Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.

According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.

The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.

ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.

Login
Username:

Password:


Related Headlines

American Lung Association announces #Act4Impact livestream event to raise funds for communities hardest hit by COVID-19

The Lancet Publishes Promising Data of Apeiron's APN01 (rhsACE2) to Treat COVID-19 in Named Patient Use

Veeva, Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data

Humanigen Inks Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab

CNS provides COVID related brain injuries & commemorates 40th anniversary of advanced care to brain injury and stroke patients

NeuroRx files for FDA's EUA for RLF-100 in the treatment of patients with critical COVID-19

FDA Accepts Supplemental New Drug Application for Pfizer's Xalkori for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

Relief Therapeutics seeks US FDA emergency approval for its drug against COVID-19

US FDA receives Emergency Use Authorisation request for NeuroRx's RLF-100 aviptadil

NeuroRx submits EUA with FDA for RLF-100 (aviptadil) in the treatment of patients with critical COVID-19 and corresponding respiratory failure

Applied Biology, Corpometria Institute Receive National IRB Approval to Study a Potential Breakthrough Therapy for COVID-19

CytoSorbents reports launch of CytoSorb in Brazil to treat cytokine storm in COVID-19 infection

Albert Einstein College of Medicine, Children's Hospital at Montefiore (CHAM) and Yale University publishes paper titled "Immune Responses to SARS-CoV-2 Infection in Hospitalized Pediatric and Adult Patients"

Ampio Pharmaceuticals wins FDA IND approval for clinical trial protocol of inhaled Ampion for COVID-19 patients with respiratory distress